Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.Frontiers in immunology · 2023
   Review
2. Detecting Tweets Containing Cannabidiol-Related COVID-19 Misinformation Using Transformer Language Models and Warning Letters From Food and Drug Administration: Content Analysis and Identification.JMIR infodemiology · 2023
   Article
3. Israeli news media coverage of COVID-19 and use of cannabis and tobacco: A case study of inconsistent risk communication.The International journal on drug policy · 2022
   Article
4. Will Cannabis or Cannabinoids Protect You from SARS-CoV-2 Infection or Treat COVID-19?Medical cannabis and cannabinoids · 2022
   Article
5. Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy.Frontiers in immunology · 2022
   Article
6. Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.Journal of personalized medicine · 2021
   Review
7. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19.International journal of molecular sciences · 2021
   Review
8. Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond.Research in social & administrative pharmacy : RSAP · 2021
   Review
9. Pharmacy practice research priorities during the COVID-19 pandemic: Recommendations of a panel of experts convened by FIP Pharmacy Practice Research Special Interest Group.Research in social & administrative pharmacy : RSAP · 2021
   Article
10. The Essential Medicinal Chemistry of Cannabidiol (CBD).Journal of medicinal chemistry · 2020
    Review
11. Intersection of the Web-Based Vaping Narrative With COVID-19: Topic Modeling Study.Journal of medical Internet research · 2020
    Article
12. Laboratory and clinical research on COVID-19: focus on non-lung organs.Conditioning medicine · 2020
    Article
13. Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).Cancer treatment reviews · 2020
    Review
14. The Prevalence of Underlying Diseases and Comorbidities in COVID-19 Patients; an Updated Systematic Review and Meta-analysis.Archives of academic emergency medicine · 2020
    Review
15. The Potential Role of Super Spread Events in SARS-COV-2 Pandemic; a Narrative Review.Archives of academic emergency medicine · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as